Quest for the right Drug
פיקטו % 0.05 PICATO 0.05% (INGENOL MEBUTATE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
חיצוני : TOPICAL
צורת מינון:
ג'ל : GEL
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Special Warning : אזהרת שימוש
4.4 Special warnings and precautions for use Eye exposure Contact with the eyes can cause chemical conjunctivitis and corneal burns. Patients should wash their hands thoroughly after applying the gel and following any contact with the treated area, to avoid inadvertent transfer of the gel to the eyes. If accidental exposure occurs, the eyes should be flushed immediately with large amounts of water, and the patient should seek medical care as soon as possible. Eye disorders such as eye pain, eyelid oedema and periorbital oedema should be expected to occur after accidental eye exposure of Picato (see section 4.8). Ingestion Picato must not be ingested. If accidental ingestion occurs the patient should drink plenty of water and seek medical care. General Administration of Picato is not recommended until the skin is healed from treatment with any previous medicinal product or surgical treatment and should not be applied to open wounds or damaged skin where the skin barrier is compromised. Picato should not be used near the eyes, on the inside of the nostrils, on the inside of the ears or on the lips. Local skin responses Local skin responses such as erythema, flaking/scaling, and crusting should be expected to occur after cutaneous application of Picato (see section 4.8). Localised skin responses are transient and typically occur within 1 day of treatment initiation and peak in intensity up to 1 week following completion of treatment. Localised skin responses typically resolve within 2 weeks of treatment initiation when treating areas on the face and scalp and within 4 weeks of treatment initiation when treating areas on the trunk and extremities. Treatment effect may not be adequately assessed until resolution of local skin responses. Sun exposure Studies have been conducted to assess the effects of UV irradiation of the skin following single and multiple applications of ingenol mebutate gel, 100 mcg/g. Ingenol mebutate gel did not demonstrate any potential for photo irritation or photo allergic effects. However, due to the nature of the disease, excessive exposure to sunlight (including sunlamps and tanning beds) should be avoided or minimised. Keratoacanthoma Reports of keratoacanthoma occurring within the treatment area with a time to onset ranging from weeks to months following use of ingenol mebutate gel have been received from a post- authorisation clinical trial (see section 5.1). Health care professionals should advise patients to be vigilant for any lesions developing within the treatment area and to seek medical advice immediately should any occur. Management of actinic keratosis Lesions clinically atypical for actinic keratosis or suspicious for malignancy should be biopsied to determine appropriate treatment.
Effects on Driving
4.7 Effects on ability to drive and use machines Picato has no or negligible influence on the ability to drive and use machines.
פרטי מסגרת הכללה בסל
א. התרופה תינתן לטיפול מקומי במבוגרים הסובלים מ-Actinic keratosis בחולים המוגדרים בסיכון גבוה (סובלים מלפחות 6 נגעים, הניתנים להבחנה, באזור גוף אחד או שדה וב- Field cancerization).ב. מתן התרופה האמורה ייעשה לפי מרשם של מומחה ברפואת עור ומין.
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
12/01/2017
הגבלות
תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת
מידע נוסף